Drug-Induced death signaling strategy rapidly predicts cancer response to chemotherapy

Cell

Volumn 160, Issue 5, 2015, Pages 977-989

  Montero, Joan ^a   Sarosiek, Kristopher A ^a   Deangelo, Joseph D ^a   Maertens, Ophélia ^a   Ryan, Jeremy ^a   Ercan, Dalia ^a   Piao, Huiying ^a   Horowitz, Neil S ^a   Berkowitz, Ross S ^a   Matulonis, Ursula ^a   Jänne, Pasi A ^a   Amrein, Philip C ^b   Cichowski, Karen ^a   Drapkin, Ronny ^a   Letai, Anthony ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOPLATIN; PHOSPHOTRANSFERASE INHIBITOR;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER MORTALITY; CONTROLLED STUDY; CYTOTOXICITY; DYNAMIC BH3 PROFILING; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRION; NONHUMAN; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CELL LINE; FEMALE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; NEOPLASMS; OVARIAN NEOPLASMS; PATHOLOGY; PERSONALIZED MEDICINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CELL LINE; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MITOCHONDRIA; NEOPLASMS; OVARIAN NEOPLASMS; PRECISION MEDICINE; SIGNAL TRANSDUCTION;

EID: 84923375991     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2015.01.042     Document Type: Article

References (35)

1. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, S. Kim, C.J. Wilson, J. Lehár, G.V. Kryukov, and D. Sonkin The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
2. A.P. Bhatt, P.M. Bhende, S.H. Sin, D. Roy, D.P. Dittmer, and B. Damania Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas Blood 115 2010 4455 4463
3. H.J. Burstein, P.B. Mangu, M.R. Somerfield, D. Schrag, D. Samson, L. Holt, D. Zelman, J.A. Ajani American Society of Clinical Oncology American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays J. Clin. Oncol. 29 2011 3328 3330
4. M. Certo, V. Del Gaizo Moore, M. Nishino, G. Wei, S. Korsmeyer, S.A. Armstrong, and A. Letai Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members Cancer Cell 9 2006 351 365
5. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
6. J.E. Chipuk, T. Moldoveanu, F. Llambi, M.J. Parsons, and D.R. Green The BCL-2 family reunion Mol. Cell 37 2010 299 310
7. A.S. Crystal, A.T. Shaw, L.V. Sequist, L. Friboulet, M.J. Niederst, E.L. Lockerman, R.L. Frias, J.F. Gainor, A. Amzallag, and P. Greninger Patient-derived models of acquired resistance can identify effective drug combinations for cancer Science 346 2014 1480 1486
8. J. Deng, N. Carlson, K. Takeyama, P. Dal Cin, M. Shipp, and A. Letai BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents Cancer Cell 12 2007 171 185
9. J. Deng, T. Shimamura, S. Perera, N.E. Carlson, D. Cai, G.I. Shapiro, K.K. Wong, and A. Letai Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion Cancer Res. 67 2007 11867 11875
10. J.A. Engelman, L. Chen, X. Tan, K. Crosby, A.R. Guimaraes, R. Upadhyay, M. Maira, K. McNamara, S.A. Perera, and Y. Song Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat. Med. 14 2008 1351 1356
11. D. Ercan, K. Zejnullahu, K. Yonesaka, Y. Xiao, M. Capelletti, A. Rogers, E. Lifshits, A. Brown, C. Lee, and J.G. Christensen Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor Oncogene 29 2010 2346 2356
12. D. Ercan, C. Xu, M. Yanagita, C.S. Monast, C.A. Pratilas, J. Montero, M. Butaney, T. Shimamura, L. Sholl, and E.V. Ivanova Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors Cancer Discov 2 2012 934 947
13. A.C. Faber, D. Li, Y. Song, M.C. Liang, B.Y. Yeap, R.T. Bronson, E. Lifshits, Z. Chen, S.M. Maira, and C. García-Echeverría Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition Proc. Natl. Acad. Sci. USA 106 2009 19503 19508
14. A.C. Faber, R.B. Corcoran, H. Ebi, L.V. Sequist, B.A. Waltman, E. Chung, J. Incio, S.R. Digumarthy, S.F. Pollack, and Y. Song BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors Cancer Discov 1 2011 352 365
15. L.A. Garraway, and P.A. Jänne Circumventing cancer drug resistance in the era of personalized medicine Cancer Discov 2 2012 214 226
16. B. Haibe-Kains, N. El-Hachem, N.J. Birkbak, A.C. Jin, A.H. Beck, H.J. Aerts, and J. Quackenbush Inconsistency in large pharmacogenomic studies Nature 504 2013 389 393
17. M. Hidalgo, F. Amant, A.V. Biankin, E. Budinská, A.T. Byrne, C. Caldas, R.B. Clarke, S. de Jong, J. Jonkers, and G.M. Mælandsmo Patient-derived xenograft models: an emerging platform for translational cancer research Cancer Discov 4 2014 998 1013
18. H. Joensuu, P.J. Roberts, M. Sarlomo-Rikala, L.C. Andersson, P. Tervahartiala, D. Tuveson, S. Silberman, R. Capdeville, S. Dimitrijevic, B. Druker, and G.D. Demetri Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N. Engl. J. Med. 344 2001 1052 1056
19. R.M. Kluck, E. Bossy-Wetzel, D.R. Green, and D.D. Newmeyer The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis Science 275 1997 1132 1136
20. S.M. Kornblau, R. Tibes, Y.H. Qiu, W. Chen, H.M. Kantarjian, M. Andreeff, K.R. Coombes, and G.B. Mills Functional proteomic profiling of AML predicts response and survival Blood 113 2009 154 164
21. A. Letai, M.C. Bassik, L.D. Walensky, M.D. Sorcinelli, S. Weiler, and S.J. Korsmeyer Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics Cancer Cell 2 2002 183 192
22. O. Maertens, B. Johnson, P. Hollstein, D.T. Frederick, Z.A. Cooper, L. Messiaen, R.T. Bronson, M. McMahon, S. Granter, and K. Flaherty Elucidating distinct roles for NF1 in melanomagenesis Cancer Discov 3 2013 338 349
23. T. Ni Chonghaile, K.A. Sarosiek, T.T. Vo, J.A. Ryan, A. Tammareddi, Vdel.G. Moore, J. Deng, K.C. Anderson, P. Richardson, and Y.T. Tai Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy Science 334 2011 1129 1133
24. J.G. Paez, P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, and T.J. Boggon EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
25. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172 discussion 207-112
26. J. Ryan, and A. Letai BH3 profiling in whole cells by fluorimeter or FACS Methods 61 2013 156 164
27. J.A. Ryan, J.K. Brunelle, and A. Letai Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes Proc. Natl. Acad. Sci. USA 107 2010 12895 12900
28. K.A. Sarosiek, X. Chi, J.A. Bachman, J.J. Sims, J. Montero, L. Patel, A. Flanagan, D.W. Andrews, P. Sorger, and A. Letai BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response Mol. Cell 51 2013 751 765
29. C.L. Sawyers Chronic myeloid leukemia N. Engl. J. Med. 340 1999 1330 1340
30. C.L. Sawyers The cancer biomarker problem Nature 452 2008 548 552
31. R. Sikorski, and B. Yao Visualizing the landscape of selection biomarkers in current phase III oncology clinical trials Sci. Transl. Med. 2 2010 34ps27
32. T.T. Vo, J. Ryan, R. Carrasco, D. Neuberg, D.J. Rossi, R.M. Stone, D.J. Deangelo, M.G. Frattini, and A. Letai Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML Cell 151 2012 344 355
33. M.C. Wei, W.X. Zong, E.H. Cheng, T. Lindsten, V. Panoutsakopoulou, A.J. Ross, K.A. Roth, G.R. MacGregor, C.B. Thompson, and S.J. Korsmeyer Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death Science 292 2001 727 730
34. M.B. Yaffe The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery and treatment Sci. Signal. 6 2013 pe13
35. W. Zhou, D. Ercan, L. Chen, C.H. Yun, D. Li, M. Capelletti, A.B. Cortot, L. Chirieac, R.E. Iacob, and R. Padera Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 462 2009 1070 1074